Technology evaluation: Ipilimumab, Medarex/Bristol-Myers Squibb

Current Opinion in Molecular Therapeutics

Volumn 7, Issue 6, 2005, Pages 588-597

  Morse, Michael A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; APTAMER; CANCER VACCINE; CP 675206; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; DOCETAXEL; GLYCOPROTEIN GP 100; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2; IMMUNOLOGICAL ADJUVANT; IMMUNOSTIMULATING AGENT; INTERLEUKIN 2; IPILIMUMAB; MDX 101; MDX 1379; MELACINE; MELANOMA VACCINE; STEROID; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANOREXIA; ARTHRALGIA; AUTOIMMUNE DISEASE; BREAST CANCER; CLINICAL TRIAL; COLITIS; COLORECTAL TUMOR; COUGHING; CYTOTOXIC T LYMPHOCYTE; DERMATITIS; DIARRHEA; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SYNTHESIS; ENTERITIS; ENTEROCOLITIS; FATIGUE; GRANULOCYTOSIS; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHYSITIS; HYPOPIGMENTATION; HYPOTHYROIDISM; IMMUNOSTIMULATION; KIDNEY CANCER; LIVER DYSFUNCTION; LYMPHOMA; MELANOMA; MENINGITIS; MYALGIA; NONHUMAN; NOSE CONGESTION; OVARY TUMOR; PROSTATE CANCER; PRURITUS; RASH; REVIEW; STRUCTURE ACTIVITY RELATION; URTICARIA; UVEITIS; VITILIGO;

ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PATENTS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 28844432420     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. 256500 Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Perez VL, Van Parijs L, Biuckians A, Zheng XX, Strom TB, Abbas AK IMMUNITY 1997 6 4 411-417
2. 287479 NeXatar obtains exclusive option to CTLA-4 blockade technology; CTLA-4 believed to play role in cancer. NeXstar Pharmaceuticals Inc PRESS RELEASE 1998 May 19
3. 317077 Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR et al NAT MED 1998 4 3 321-327
4. 338426 Medarex signs development agreement with Gilead for anti-CTLA-4 therapeutics. Medarex Inc PRESS RELEASE 1999 August 31
5. 351605 Medarex and IDM announce broad antibody development agreement and anti-CTLA-4 cancer vaccine partnership. Medarex Inc PRESS RELEASE 1999 December 29
6. 427417 Medarex reveals MDX-010 interim results. Medarex Inc PRESS RELEASE 2001 October 30
7. 439049 Phage Display Technologies - SMi Conference, London, UK. Jermutus L IDDB MEETING REPORT 2002 January 23-24
8. 451023 MDX-010 (human anti-CTLA4): A phase I trial in malignant melanoma. Tchekmedyian S, Glasby J, Korman A, Keler T, Deo Y, Davis TA PROC AM SOC CLIN ONCOL 2002 21 1 Abs 56
9. 451188 MDX-010 (human anti-CTLA4): A phase 1 trial in hormone refractory prostate carcinoma (HRPC). Davis TA, Tchekmedyian S, Korman A, Keler T, Deo Y, Small EJ PROC AM SOC CLIN ONCOL 2002 21 1 Abs 74
10. 452248 American Society of Clinical Oncology - 38th Annual Meeting (Part VII) Orlando, FL, USA. Evans L IDDB MEETING REPORT 2002 May 18-21
11. 454392 Medarex and IDM develop Cell Drugs with MDX-010. Medarex Inc PRESS RELEASE 2002 June 11
12. 468326 Medarex starts further phase II trials of MDX-010. Medarex Inc PRESS RELEASE 2002 October 29
13. 484372 Cancer Vaccines and Immunotherapy - Fifth Annual Colloqulum (Part I), Models for Cancer Vaccines, Walker's Cay, Bahamas. Salgaller M IDDB MEETING REPORT 2003 March 05-08
14. 485087 Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, Davis T, Henry Spires R, MacRae S, Willman A, Padera R et al PROC NATL ACAD SCI USA 2003 100 8 4712-4717
15. 489881 Cancer Vaccines 2003 - Knowledge Foundation Second International Conference on Advances in Designing Cancer Vaccines, Boston, MA, USA. Salgaller M IDDB MEETING REPORT 2003 April 24-25
16. 492036 Phase I trial of antibody to CTLA-4 (MDX-010) with melanoma peptides/Ifa for resected stages III/V melanoma. Weber JS, Snively J, Sian S, Lau R, Lee P, Scotland R, Davis T PROC AM SOC CLIN ONCOL 2003 22 Abs 2853
17. 492119 Blockade of CTLA-4 with MDX-010 in humans can induce both autoimmunity and cancer regression. Phan GQ, Haworth LR, Duray PH, Davis TA, Rosenberg SA PROC AM SOC CLIN ONCOL 2003 22 Abs 3424
18. 493173 Medarex initiates phase I trial of MDX-010 against HIV. Medarex Inc PRESS RELEASE 2003 June 11
19. 494716 Anti-cancer responses in metastatic melanoma patients linked to immune activation by MDX-010 published in the 'Proceedings of the National Academy of Sciences' (PNAS). Medarex Inc PRESS RELEASE 2003 June 25
20. 496461 International Melanoma Research Congress - Foundation for Melanoma Research, Philadelphia, PA, USA. Swart G IDDB MEETING REPORT 2003 June 21-24
21. 504343 Medarex expands MDX-010 program with phase II breast cancer trial. Medarex Inc PRESS RELEASE 2003 September 08
22. 511848 Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE et al PROC NATL ACAD SCI USA 2003 100 14 8372-8377
23. 516407 A pilot study of MDX-010 after vaccine failure in patients with advanced malignancy. Janik JE, Morris JC, Quinn C, Gao W, Waldmann TA, Wilson WH, Kwak LW, Pittaluga S, Neelapu S, Streicher H, Berzofsky JA et al BLOOD 2003 102 11 Abs 2391
24. 519349 Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. Keler T, Halk E, Vitale L, O'Neill T, Blanset D, Lee S, Srinivasan M, Graziano RF, Davis T, Lonberg N, Korman A J IMMUNOL 2003 171 11 6251-6259
25. 519359 Enhancement of antitumor immunity by CTLA-4 blockade. Leach DR, Krummel MF, Allison JP SCIENCE 1996 271 5256 1734-1736
26. 524883 Medarex's revenue falls in 2003. Medarex Inc PRESS RELEASE 2004 February 26
27. 527843 Drug Discovery Technology Europe 2004 - IBC's Eighth Annual Conference (Part II), Biopharmaceuticals: Opportunities and Challenges, London, UK. Ilag VL IDDB MEETING REPORT 2004 March 09-10
28. 533872 Medarex Inc. Medarex Inc FORM 10-K 2004 March 01
29. 535135 Medarex announces 2003 fourth quarter and year-end financial results. Medarex Inc PRESS RELEASE 2004 February 26
30. 543568 Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody blockade in patients previously vaccinated with irradiated, autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor (GM-CSF). Hodi FS PROC AM SOC CLIN ONCOL 2004 23 Abs 2536
31. 543643 Medarex's MDX-060 shows promise in Hodgkin's disease trial; MDX-010 gets Orphan status. Medarex Inc PRESS RELEASE 2004 June 09
32. 547006 Form 10K for year ending December 31, 2003. Cell Genesys Inc FORM 10-K2004 March 04
33. 548774 American Society of Clinical Oncology - 40th Annual Meeting (Part X), New Orleans, LA, USA. Sondak VK IDDB MEETING REPORT 2004 June 05-08
34. 555835 Medarex reaches SPA with FDA for phase III melanoma trial. Medarex Inc PRESS RELEASE 2004 August 23
35. 557257 Drug Discovery Technology 2004 - IBC's Ninth Annual World Congress (Part II), Advances in Biotherapeutic Discovery, Boston, MA, USA. Zhu Z IDDB MEETING REPORT 2004 August 08-13
36. 558687 Medarex and Cell Genesys's anticancer combination therapy enters clinic. Medarex Inc PRESS RELEASE 2004 September 13
37. 560046 Monoclonal Antibodies in Cancer - Fourth International Congress (Part II), Colorado Springs, CO, USA. Zhu Z IDDB MEETING REPORT 2004 Sept 03-06
38. 561284 Medarex begins phase III melanoma trial of MDX-010 and MDX-1379. Medarex Inc PRESS RELEASE 2004 September 28
39. 562382 Medarex's MDX-010 receives Fast Track status for melanoma. Medarex Inc PRESS RELEASE 2004 October 05
40. 569419 Medarex and BMS collaborate on anticancer products. Bristol-Myers Squibb Co, Medarex Inc PRESS RELEASE 2004 November 08
41. 572056 Bristol-Myers Squibb R&D review. Bristol-Myers Squibb Co COMPANY PRESENTATION 2004 November 17
42. 575510 FTC extends BMS and Medarex MDX-010 collaboration review period. Medarex Inc PRESS RELEASE 2004 December 10
43. 577997 Antibody Therapeutics - IBC's Second Annual International Conference (Part II), Advances and Strategies of the Development of Antibody Therapeutic Pipeline, San Diego, CA, USA. IDdb author IDDB MEETING REPORT 2005 November 30 - December 03
44. 587419 Medarex reports $186.5 million 2004 loss. Medarex Inc PRESS RELEASE 2005 February 28
45. 588452 Medarex and BMS's MDX-010/IL-2 therapy shows benefit in melanoma study. Medarex Inc, Bristol-Myers Squibb Co PRESS RELEASE 2005 March 07
46. 598080 Durable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma. Fischkoff SA, Hersh E, Weber J, Powderly J, Khan K, Pavlick A, Samlowski W, O'Day S, Nichol G, Yellin M PROC AM SOC CLIN ONCOL 2005 24 Abs 7525
47. 603341 Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX-010). Yang JC, Beck KE, Blansfield JA, Tran KQ, Lowy I, Rosenberg SA PROC AM SOC CLIN ONCOL 2005 24 Abs 2501
48. 609110 Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, Sian S, Nichol G, Davis T, Weber J J CLIN ONCOL 2005 23 4 741-750
49. 623891 The nature of molecular recognition by T cells. Davis SJ, Ikemizu S, Evans EJ, Fugger L, Bakker TR, van der Merwe PA NAT IMMUNOL 2003 4 3 217-224
50. 623892 Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Salomon B, Bluestone JA ANNU REV IMMUNOL 2001 19 225-252
51. 623893 Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: Comparison of prophylaxis and therapy. van Elsas A, Sutmuller RP, Hurwitz AA, Ziskin J, Villasenor J, Medema JP, Overwijk WW, Restifo NP, Melief CJ, Offringa R, Allison JP J EXP MED 2001 194 4 481-490
52. 623894 CTLA-4 blockade synergizes with tumor-derived GM-CSF for treatment of an experimental mammary carcinoma. Hurwitz AA, Yu TF, Leach DR, Allison JP PROC NATL ACAD SCI USA 1998 95 17 10067-10071
53. 623900 Combination immunotherapy of primary prostate cancer in a transgenic model using CTLA-4 blockade. Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM, Burg MB, Allison JP CANCER RES 2000 60 9 2444-2448
54. 623901 CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. Espenschied J, Lamont J, Longmate J, Pendas S, Wang Z, Diamond DJ, Ellenhorn JD J IMMUNOL 2003 170 6 3401-3407
55. 623967 CTLA-4 differentially regulates T cell responses to endogenous tissue protein versus exogenous immunogen. Walker LS, Ausubel LJ, Chodos A, Bekarian N, Abbas AK J IMMUNOL 2002 169 11 6202-6209
56. 623969 Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. van Elsas A, Hurwitz AA, Allison JP J EXP MED 1999 190 3 355-366
57. 623970 Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP at al J CLIN ONCOL 2003 23 25 6043-6053
58. 623971 Phase I clinical trial of anti-CTLA-4 human monoclonal antibody CP-675,206 in patients (pts) with advanced solid malignancies. Camacho LM, Ribas A, Glaspy JA, Lopez-Berestein G, Reuben JM, Parker C, Seja E, Comin-Anduix B, Bulanhagui C, Gomez-Navarro J PROC AM SOC CLIN ONCOL 2004 22 Abs 2505
59. 623994 Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, Sian S, Nichol G, Davis T, Keler T, Yellin M, Weber J J CLIN ONCOL 2005 23 4 741-750
60. 624007 Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Santulli-Marotto S, Nair SK, Rusconi C, Sullenger B, Gilboa E CANCER RES 2003 63 21 7483-7489
61. 624016 Phase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma. Ribas A, Bozon VA, Lopez-Berestein G, Pavlov D, Reuben JM, Parker CA, Seja E, Glaspy JA, Gomez-Navarro J, Camacho LH PROC AM SOC CLIN ONCOL 2005 23 Abs 7524
62. 628448 Clinicaltrials.gov - ipilimumab (MDX-010). National Institutes of Health INTERNET SITE 2005 October 13 (www.clinicaltrials.gov)